SHRINK BRAIN-CANCER TUMOURS
INCREASE SURVIVAL TIME
Spanish researchers, with Tilray’s support, are hoping a cocktail of THC, CBD and the chemotherapy drug TMZ can shrink brain-cancer tumours and increase survival rates for patients suffering an aggressive form of brain cancer called glioblastoma multiforme.
Clinical-trial records updated on February 7, 2019 say the study is slated to start in March 2019.
Primary completion is expected by June 2020.
THC, CBD and chemo drug
Patients will be treated in the Spanish cities of Barcelona, Mallorca and Valencia.
Other sponsors and collaborators include:
- Grupo Español de Investigación en Neurooncología
- Medical Cannabis Bike Tour
- Voices Against Brain Cancer
Positive results published
The MZ/THC/CBD combo showed “a strong anti-tumoral effect” in experimental research published Biochemical Pharmacology in November 2018.
The Spanish researchers found that tumor-cell samples could be “therapeutically exploited for the management of Glioblastoma.”
GW Pharmaceuticals study
The results of a clinical trial completed by GW Pharmaceuticals in 2016 have not been published, but the company subsequently announced a 83% survival rate among 21 patients, compared with 53% in the placebo group.